SIBR Research

SIBR Research is a biotechnology company that specialized in the development of RNA interference (RNAi) therapeutics, particularly for oncology applications. The company's core technology is the Small Interfering Biopolymer Research (SIBR) platform, a delivery system designed to protect and transport small interfering RNA (siRNA) to target cells. Their primary research focus involved silencing the Ribonucleotide Reductase M2 (RRM2) gene, which is often overexpressed in various cancers and contributes to tumor growth and drug resistance. SIBR Research aimed to treat aggressive malignancies such as pancreatic cancer and melanoma using these targeted molecular therapies. Although the company made strides in pre-clinical development and received federal research grants, it is no longer actively operating.